Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer.
Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer. Gynecol Oncol. 2018 10; 151(1):46-52.
-
Aged
-
Aged
-
Aged, 80 and over
-
Aged, 80 and over
-
Antibodies, Monoclonal, Humanized
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Combined Chemotherapy Protocols
-
Antineoplastic Combined Chemotherapy Protocols
-
Carboplatin
-
Carboplatin
-
Cohort Studies
-
Cohort Studies
-
Diarrhea
-
Diarrhea
-
Disease-Free Survival
-
Disease-Free Survival
-
Drug Resistance, Neoplasm
-
Drug Resistance, Neoplasm
-
Fallopian Tube Neoplasms
-
Fallopian Tube Neoplasms
-
Fatigue
-
Fatigue
-
Female
-
Female
-
Folate Receptor 1
-
Folate Receptor 1
-
Humans
-
Humans
-
Immunoconjugates
-
Immunoconjugates
-
Incidence
-
Incidence
-
Maximum Tolerated Dose
-
Maximum Tolerated Dose
-
Maytansine
-
Maytansine
-
Middle Aged
-
Middle Aged
-
Nausea
-
Nausea
-
Neoplasm Recurrence, Local
-
Neoplasm Recurrence, Local
-
Ovarian Neoplasms
-
Ovarian Neoplasms
-
Thrombocytopenia
-
Thrombocytopenia
-
Treatment Outcome
-
Treatment Outcome